Craig Martin

Craig is an experienced executive, advisor and board director, with deep expertise in biotech and health technology markets. He has led both for-profit and non-profit organizations focused on developing and expanding access to treatments for rare, genetic conditions, and worked extensively on advancing new technologies and treatment modalities – including gene editing and gene therapy, mRNA, genomic sequencing and molecular diagnostics. In June 2024, Craig founded Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on reinitiating development and commercializing, through its subsidiary Orphan Therapies, promising treatments for ultra-rare diseases. OTXL has also partnered with ASGCT to establish CGTxchange, an AI-enabled marketplace to match shelved therapeutic assets with investors and partners to continue their development. He’s held leadership positions with companies based in Cambridge, MA, Washington, D.C., New York and Brussels, Belgium.